As the nation continues to grapple with the opioid crisis, the search for safer alternatives to manage chronic pain has intensified. Gabapentin, an anticonvulsant originally approved for seizure disorders and postherpetic neuralgia – nerve pain following shingles – has seen a dramatic rise in prescriptions over the last decade. While often positioned as a less risky option than opioids, emerging research suggests that gabapentin is not without its own potential drawbacks, raising questions about its widespread use.
Gabapentin works by modulating nerve activity, calming overactive signals in the brain and nervous system through interactions with calcium channels. It’s classified as a GABA analogue, mimicking the neurotransmitter gamma-aminobutyric acid, which helps reduce nerve excitability. Beyond its FDA-approved uses, it’s frequently prescribed “off-label” for a variety of chronic pain conditions. However, a growing body of evidence indicates that increased gabapentin use may be linked to cognitive issues and other concerning side effects.
Prescriptions for gabapentin more than doubled between 2010 and 2024, with nearly 15.5 million Americans receiving a prescription in 2024, making it the fifth most dispensed drug in U.S. Retail pharmacies, according to a September 2025 report by researchers at the Centers for Disease Control and Prevention published in Annals of Internal Medicine [FDA Warning]. This surge coincides with heightened awareness of the opioid epidemic and a shift in prescribing practices.
Cognitive Risks and Long-Term Use
Recent studies have raised concerns about a potential link between long-term gabapentin use and cognitive decline. Research published in Regional Anesthesia & Pain Medicine in 2025 found that chronic pain patients who received six or more gabapentin prescriptions over a 10-year period had a significantly higher incidence of mild cognitive impairment and dementia compared to those who did not take the medication. Specifically, dementia risk was more than doubled, and mild cognitive impairment risk was more than tripled among individuals aged 35 to 49. Similar results were observed in the 50-64 age group.
The study, a retrospective cohort analysis of over 26,000 adults diagnosed with chronic low back pain using the TriNetX national database, excluded individuals with pre-existing conditions like dementia, epilepsy, stroke, or cancer. The increased risk correlated with prescription frequency; those receiving 12 or more prescriptions experienced a higher incidence of both cognitive impairment and dementia than those prescribed the drug 3-11 times.
Prescribing Cascades and Unclear Guidance
Beyond cognitive risks, concerns are emerging about “prescribing cascades” – a pattern where side effects of one medication are treated with another. An analysis in JAMA Network Open highlighted that clinicians often fail to recognize gabapentinoid-induced edema (swelling) and instead attribute it to conditions like congestive heart failure or venous stasis, leading to inappropriate treatment with diuretics. The study of military veterans found that nearly one in four patients experienced potential harm from this prescribing cascade [Drugs.com – Gabapentin].
A 2025 review in the European Journal of Pain revealed a global lack of clear guidance for clinicians regarding the initiation, monitoring, and tapering of gabapentinoid use, contributing to uncertainty and potentially inappropriate prescribing practices [Harvard Health Publishing – Gabapentin].
Self-Harm and Monitoring
Long-standing concerns about a potential link between gabapentin and self-harm have also been revisited. A U.K. Self-controlled case series published in the BMJ in April 2025 found that the risk of self-harm increased in the 90 days before starting gabapentin, persisted during early treatment, and rose again after stopping the medication. While the study did not establish a direct causal link, it underscores the importance of careful patient monitoring throughout the course of treatment [FDA Drug Safety Communication].
Common side effects of gabapentin include drowsiness, dizziness, blurred vision, and difficulty with coordination and concentration. Chronic pain itself is a debilitating condition, and it’s crucial that treatment approaches minimize the potential for additional complications.
The increasing complexity surrounding gabapentin highlights the need for a cautious and individualized approach to pain management. Further research is essential to fully understand the long-term effects of this widely prescribed medication and to develop more effective and safer strategies for managing chronic pain. What comes next will likely involve more refined prescribing guidelines and increased vigilance regarding potential adverse effects.
Have you or someone you know been prescribed gabapentin? Share your experiences in the comments below.
Disclaimer: This article provides informational content and should not be considered medical advice. Please consult with a qualified healthcare professional for any health concerns or before making any decisions related to your health or treatment.
